Dual-organ toxicity during treatment with nivolumab and ipilimumab in combination with chemotherapy in the first-line treatment of non-small cell lung cancer

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). The combination of nivolumab and ipilimumab with two cycles of chemotherapy improves treatment efficacy; however, this combination therapy is also associated with a high incidence of adverse...

Descripció completa

Dades bibliogràfiques

Autors principals:	Agnieszka Dyzma-Kasprzak, Karol Kasprzak, Elżbieta Szczepaniak-Wójtowicz, Joanna Milanowska, Izabela Chmielewska, Paweł Krawczyk
Format:	Artigo
Idioma:	Inglês
Publicat:	Via Medica 2026-09-01
Col·lecció:	Oncology in Clinical Practice
Matèries:	NSCLC immunotherapy multi-organ toxicity pneumonitis colitis
Accés en línia:	https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/101315
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!